JY-232

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameJY-232
Drug Alias Namein vivo Chimeric Antigen Receptor T-cell (CAR-T) therapy (Genocury Biotech)JY232JY-232
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Genocury Biotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Genocury Biotech Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A